🏅 FDA Orphan Designation

GATTEX

teduglutide [rDNA origin]

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.

Indicated for:

Primary short bowel syndromeOrphan

FDA-Approved Indications (1)

Primary short bowel syndromeOrphan Designation

Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support

Indications & Usage

1 INDICATIONS AND USAGE GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )

💙 Support Programs

View all →

Gattex

Takeda

Copay card ↗Apply ↗

GATTEX

Takeda Pharmaceuticals U.S.A., Inc.

Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.